International Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis

N/ATerminatedNCT02041624

Stallergenes Greer740 enrolled

Overview

The purpose of the present study is to describe patient's perception of quality of life and effectiveness of ORALAIR® over a follow-up period up to 5 years, in real-life settings.

Primary objective: To describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass pollen season in real-life settings. Secondary objectives: \- To describe the patient's perceived effectiveness of ORALAIR® in allergic rhinoconjunctivitis management in terms of disease intensity, satisfaction and rescue medication

Study Type

OBSERVATIONAL

Enrollment

740

Conditions

Allergic Rhinitis Due to Grass Pollens

Eligibility

Sex: ALLMin age: 5 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient of 5 years of age and older at the date of the screening visit * Patient with proven allergic rhino-conjunctivitis due to grass pollen * Patient eligible for a grass-pollen Allergen ImmunoTherapy (AIT) * Patient whose physician prescribed ORALAIR® independently of the study, before the beginning of the grass-pollen season Exclusion Criteria: * Patient participating in a clinical trial or in an epidemiological study

Locations (1)

Laboratoire Stallergenes

Antony, France

Outcomes

Primary Outcomes

Health related quality of life

The primary objective is to describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass-pollen season in real-life settings.

Time frame: patients will be followed for the duration of the treatment, an expected average of 6 months/year

Secondary Outcomes

Treatment Effectiveness

To describe the patient's perceived effectiveness of ORALAIR® in allergic rhino-conjunctivitis management in terms of disease intensity, satisfaction and rescue medication

Time frame: patients will be followed for the duration of the treatment, an expected average of 6 months/year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.